Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7934636 | 0.84 | CHRM1 (0.48) | ERN1HSP90AA1HSP90AB1 | |
| SCHEMBL5735298 | 0.83 | ERN1 (0.52) | ERN1TLR2TLR1TLR6 | |
| SCHEMBL15674880 | 0.82 | PTGER1 (0.52) | ERN1PIK3CATLR2TLR1TLR6 | |
| SCHEMBL31364059 | 0.80 | ERN1 (0.55) | ERN1TLR2TLR1TLR6 | |
| SCHEMBL1043113 | 0.80 | ERN1 (0.55) | ERN1TLR2TLR1TLR6 | |
| SCHEMBL2562740 | 0.80 | ERN1 (0.47) | ERN1TLR2TLR1TLR6CA12 | |
| SCHEMBL3967846 | 0.80 | ERN1 (0.47) | ERN1ALOX15ALOX12TLR2TLR1 | |
| SCHEMBL16439936 | 0.78 | ERN1 (0.67) | ERN1TLR2TLR1TLR6 | |
| SCHEMBL31152506 | 0.78 | ERN1 (0.67) | ERN1TLR2TLR1TLR6 | |
| SCHEMBL6525704 | 0.78 | CHRM1 (0.38) | ERN1ALOX5CA12CA9MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244446-B1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| US-6858630-B2 | Naphthimidazole derivatives and their use as thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-1244446-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1244446-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001039773-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | MPL, THPO, TPO | ERN1 2498/4885ALOX5 3285/4885PIK3CA 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.